HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

670.135

+9.6471.46%

Number of Gainers:17

Number of Losers:13

Number of Flat:4

PE:- -

High:678.126

Open:660.587

Low:657.123

Close:660.489

Volume:153.72M

Turnover:4.63B

Market Cap:429.95B

Float Cap:380.25B

Loading ...

Innovative Drugs Lead the Charge as Huabao Fund's Hong Kong Stock Connect Innovative Drug ETF (520880) Surges 6% on Heavy Volume

Biopharma Firms Report Widespread Profit Doubling, HK Stock Connect Drug Stocks Surge Again, 520880 Rapidly Approaches 5%! HK Stock Connect Healthcare Also Rises, 159137 Touches 4% High

ETF Daily: Healthcare Sector Poised for New Growth Logic Amid AI Tech Wave, Brain-Computer Interfaces and AI Medicine Advance Rapidly

HBM Holdings grants 103,000 nil-price share awards to employee

Venus MedTech FY25 net loss narrows 43.2% to RMB 410 million; revenue falls 34.8% to RMB 310 million

Alphamab Oncology says Phase III KN026 neoadjuvant HER2+ breast cancer trial meets primary endpoint

SinoMab BioScience says non-executive directors Chen, Dong resign

SinoMab BioScience files list of directors with Hong Kong Stock Exchange

Akeso says ivonescimab improves quality of life vs pembrolizumab in Phase III NSCLC study

BRIEF-Ascletis Pharma FY Loss Attributable Rmb359.9 Million

HBM HOLDINGS-B (02142) Grants 103,000 Share Awards

BRIEF-Venus Medtech Hangzhou Logs FY Revenue RMB 306.8 Mln

Institutional Visits to Over 600 Listed Companies in March Highlight Strong Interest in Tech Manufacturing and Pharmaceuticals

ASCLETIS-B Reports Annual Loss Attributable to Shareholders of 360 Million Yuan, Widening 19.6% Year-on-Year

Ascletis Pharma Inc - FY Loss Attributable RMB359.9 Mln

THOMSON REUTERS

BRIEF-Alphamab Oncology Says Phase III Study Of KN026 With HB1801 Met Primary Endpoint

VENUS MEDTECH-B Reports Annual Results: Shareholder Loss Narrows 42.9% to 408 Million Yuan

Venus Medtech Hangzhou FY Revenue RMB 306.8 Million

THOMSON REUTERS

ALPHAMAB-B (09966): Phase III Trial of KN026 as Neoadjuvant Therapy for HER2-Positive Breast Cancer Meets Primary Endpoint

Alphamab Oncology - Phase Iii Study of Kn026 With Hb1801 for Her2+ Bc Met Primary Endpoint

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1574/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":670.1354,"timestamp":1775117299351,"preClose":660.4887,"halted":0,"volume":153717417,"delay":0,"changeRate":0.014605,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed Easter Monday","change":9.646667,"latestTime":"04-02 16:00:00","open":660.58655,"high":678.1257,"low":657.12256,"amount":4633342498,"amplitude":0.031799,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"pbRate":5.274197,"peRate":-86.845688,"turnoverRate":0.005552,"increases":17,"decrements":14,"flats":2,"marketCap":429946652416,"floatMarketCap":380251567184},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":678.1257,"amplitude":0.031799,"preClose":660.4887,"low":657.12256,"pbRate":"5.274197","latestPrice":670.1354,"volume":153717417,"delay":0,"open":660.58655,"prevYearClose":556.26263,"prevWeekClose":670.135,"prevMonthClose":610.821,"prevQuarterClose":610.821,"fiveDayClose":579.36,"twentyDayClose":522.155,"sixtyDayClose":580.971,"secType":"PLATE","market":"HK","turnoverRate":0.005552,"peRate":-86.845688,"marketCap":429946652416,"floatMarketCap":380251567184,"timestamp":1775117299351,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":17,"down":13,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1156487336","title":"Innovative Drugs Lead the Charge as Huabao Fund's Hong Kong Stock Connect Innovative Drug ETF (520880) Surges 6% on Heavy Volume","url":"https://stock-news.laohu8.com/highlight/detail?id=1156487336","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156487336?lang=en_us&edition=fundamental","pubTime":"2026-04-01 11:40","pubTimestamp":1775014849,"startTime":"0","endTime":"0","summary":"On April 1, innovative drug stocks led the Hong Kong market with strong gains. The Huabao Hong Kong Stock Connect Innovative Drug ETF (520880), which focuses exclusively on innovative drug R&D...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","159137","159992","520880","BK4588","BK1161","06978","VXUS","159891","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100509916","title":"Biopharma Firms Report Widespread Profit Doubling, HK Stock Connect Drug Stocks Surge Again, 520880 Rapidly Approaches 5%! HK Stock Connect Healthcare Also Rises, 159137 Touches 4% High","url":"https://stock-news.laohu8.com/highlight/detail?id=1100509916","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100509916?lang=en_us&edition=fundamental","pubTime":"2026-04-01 10:42","pubTimestamp":1775011345,"startTime":"0","endTime":"0","summary":"On April 1, signals of easing geopolitical tensions prompted a global market rebound, with Hong Kong stocks quickly recovering and healthcare assets once again taking the lead. The Huabao Hong Kong...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159137","159992","159891","BK4585","520880","BK4588","VXUS","BK1574","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115745302","title":"ETF Daily: Healthcare Sector Poised for New Growth Logic Amid AI Tech Wave, Brain-Computer Interfaces and AI Medicine Advance Rapidly","url":"https://stock-news.laohu8.com/highlight/detail?id=1115745302","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115745302?lang=en_us&edition=fundamental","pubTime":"2026-04-01 08:31","pubTimestamp":1775003506,"startTime":"0","endTime":"0","summary":"The A-share market experienced a volatile session today, with the Shanghai Composite Index declining by 0.80%, the Shenzhen Component Index falling by 1.81%, and the ChiNext Index dropping by 2.70%....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","159891","BK1574","BK4585","09939","AIPO","AGIX","BK4550","FDN","BK4588","CHAT","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624055611","title":"HBM Holdings grants 103,000 nil-price share awards to employee","url":"https://stock-news.laohu8.com/highlight/detail?id=2624055611","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624055611?lang=en_us&edition=fundamental","pubTime":"2026-04-01 06:10","pubTimestamp":1774995035,"startTime":"0","endTime":"0","summary":"HBM Holdings granted 103,000 nil-cost share awards under its share award scheme on March 31, 2026.Shares were priced at HK$13.10 on grant date.Vesting schedule sets 25% to vest on Dec. 31, 2027.Another 25% is slated to vest on Dec. 31, 2028.Remaining 50% is set to vest on Dec. 31, 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 31, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL5kjgcG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624155537","title":"Venus MedTech FY25 net loss narrows 43.2% to RMB 410 million; revenue falls 34.8% to RMB 310 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624155537","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624155537?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:31","pubTimestamp":1774992662,"startTime":"0","endTime":"0","summary":"Venus Medtech posted a net loss attributable to owners of RMB 408 million, narrowing 42.9%, with loss per share at RMB 0.93.Revenue fell 34.8% to RMB 307 million, due to lower unit prices and sales volumes amid fiercer competition in China.Adjusted non-IFRS EBITDA was RMB 250 million, little changed with a 1.3% improvement.Overseas revenue rose 19.2% to RMB 98.3 million, while cash and cash equivalents declined 46.9% to RMB 158 million.Pipeline updates included full enrollment of 150 patients for Cardiovalve’s EU pivotal trial with CE MDR submission, while VenusP-Valve’s U.S. IDE pivotal study stayed on track.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL13PGY6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02500","BK1100","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624553015","title":"Alphamab Oncology says Phase III KN026 neoadjuvant HER2+ breast cancer trial meets primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2624553015","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624553015?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:25","pubTimestamp":1774992342,"startTime":"0","endTime":"0","summary":"Alphamab Oncology reported Phase III Neo-Healer study KN026-004 met primary endpoint in neoadjuvant treatment of HER2+ breast cancer.Trial showed KN026 with albumin-bound docetaxel HB1801, with or without carboplatin, improved complete response outcomes versus current standard regimen.Detailed results will be presented at an international academic conference in near future.Study planned enrollment about 520 patients across multiple centers.Update supports broader late-stage development strategy for KN026 across HER2+ breast cancer, gastric cancer indications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the Issuer Information Service operated b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL94xsvV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624584965","title":"SinoMab BioScience says non-executive directors Chen, Dong resign","url":"https://stock-news.laohu8.com/highlight/detail?id=2624584965","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624584965?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:59","pubTimestamp":1774990769,"startTime":"0","endTime":"0","summary":"SinoMab BioScience said non-executive director Haigang Chen will step down effective March 31, 2026.Non-executive director Xun Dong will resign effective April 1, 2026.Board will retain Shui On Leung as executive director, chairman, and CEO.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 31, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLcb3DmH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","03681","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624452558","title":"SinoMab BioScience files list of directors with Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2624452558","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624452558?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:58","pubTimestamp":1774990717,"startTime":"0","endTime":"0","summary":"SinoMab BioScience filed updated board composition for Hong Kong Stock Exchange, naming Shui On Leung as chairman and chief executive officer.Board includes two non-executive directors, including Xun Dong.Board includes five independent non-executive directors, including Ping Cho Terence Hon.Hon chairs audit committee; Chi Ming Lee chairs remuneration committee.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 31, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLHTsdT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","03681","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624530051","title":"Akeso says ivonescimab improves quality of life vs pembrolizumab in Phase III NSCLC study","url":"https://stock-news.laohu8.com/highlight/detail?id=2624530051","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624530051?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:40","pubTimestamp":1774989618,"startTime":"0","endTime":"0","summary":"Akeso presented health-related quality-of-life results from Phase III HARMONi-2 at ELCC 2026 for ivonescimab versus Merck’s Keytruda in first-line PD-L1-positive non-small cell lung cancer.Patient-reported outcomes indicated ivonescimab improved overall well-being and daily functioning versus Keytruda in chemotherapy-free treatment.Symptom measures showed better control of key lung cancer symptoms, with a sustained advantage in breathing-related complaints.Akeso positioned findings as supportive of broader uptake, citing prior HARMONi-2 efficacy results that outperformed Keytruda in a head-to-head study.Ivonescimab has been marketed in China since 2025 for this setting, strengthening Akeso’s push to establish it as a new standard of care.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL7F4bc7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","IE00B543WZ88.USD","BK1161","LU0348783233.USD","LU0348827113.USD","LU1720050803.USD","LU2399975544.HKD","BK1574","LU1794554557.SGD","LU2476274720.SGD","LU2488822045.USD","LU0417516902.SGD","LU0348784397.USD","LU0634319403.HKD","LU0417516738.SGD","LU0348766576.USD","LU0348767384.USD","LU1961090484.USD","LU2778985437.USD","IE00BPRC5H50.USD","LU0348735423.USD","LU0540923850.HKD","IE00B5MMRT66.SGD","LU2476274308.USD","LU0348825331.USD","LU0417516571.SGD","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624539658","title":"BRIEF-Ascletis Pharma FY Loss Attributable Rmb359.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624539658","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624539658?lang=en_us&edition=fundamental","pubTime":"2026-04-01 00:45","pubTimestamp":1774975539,"startTime":"0","endTime":"0","summary":"BRIEF-Ascletis Pharma FY Loss Attributable Rmb359.9 MillionMarch 31 (Reuters) - Ascletis Pharma Inc 1672.HK:ASCLETIS PHARMA INC - FY LOSS ATTRIBUTABLE RMB359.9 MILLIONFurther company coverage: 1672.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J1FZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01672","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114539082","title":"HBM HOLDINGS-B (02142) Grants 103,000 Share Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=1114539082","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114539082?lang=en_us&edition=fundamental","pubTime":"2026-03-31 23:48","pubTimestamp":1774972094,"startTime":"0","endTime":"0","summary":"HBM HOLDINGS-B (02142) announced that on March 31, 2026, pursuant to the share award scheme adopted by shareholders on November 23, 2020, the company granted 103,000 share awards to a qualified participant. The grant is subject to acceptance by the grantee.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623435533","title":"BRIEF-Venus Medtech Hangzhou Logs FY Revenue RMB 306.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623435533","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623435533?lang=en_us&edition=fundamental","pubTime":"2026-03-31 23:26","pubTimestamp":1774970776,"startTime":"0","endTime":"0","summary":"BRIEF-Venus Medtech Hangzhou Logs FY Revenue RMB 306.8 MlnMarch 31 (Reuters) - Venus Medtech Hangzhou Inc 2500.HK:FY REVENUE RMB 306.8 MILLIONFY LOSS ATTRIBUTABLE RMB407.7 MILLIONFurther company coverage: 2500.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nPLX697C11:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1100","02500","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108318168","title":"Institutional Visits to Over 600 Listed Companies in March Highlight Strong Interest in Tech Manufacturing and Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=1108318168","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108318168?lang=en_us&edition=fundamental","pubTime":"2026-03-31 22:50","pubTimestamp":1774968652,"startTime":"0","endTime":"0","summary":"In March 2026, institutional research activity in the A-share market remained robust. Wind data statistics indicate that 666 listed companies received institutional visits during the month, spanning...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","09939","BK1161","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165768804","title":"ASCLETIS-B Reports Annual Loss Attributable to Shareholders of 360 Million Yuan, Widening 19.6% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1165768804","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165768804?lang=en_us&edition=fundamental","pubTime":"2026-03-31 22:36","pubTimestamp":1774967774,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) has announced its annual results for the period ended December 31, 2025. The group recorded total revenue of 127 million Chinese yuan, representing a 5.2% increase compared to the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1515","01477","BK1191","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623580984","title":"Ascletis Pharma Inc - FY Loss Attributable RMB359.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623580984","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623580984?lang=en_us&edition=fundamental","pubTime":"2026-03-31 22:18","pubTimestamp":1774966712,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J1FZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1161","BK1574","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623582792","title":"BRIEF-Alphamab Oncology Says Phase III Study Of KN026 With HB1801 Met Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2623582792","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623582792?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:38","pubTimestamp":1774964319,"startTime":"0","endTime":"0","summary":"BRIEF-Alphamab Oncology Says Phase III Study Of KN026 With HB1801 Met Primary EndpointMarch 31 (Reuters) - Alphamab Oncology 9966.HK:PHASE III STUDY OF KN026 WITH HB1801 FOR HER2+ BC MET PRIMARY ENDPOINTFurther company coverage: 9966.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J0GA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179334791","title":"VENUS MEDTECH-B Reports Annual Results: Shareholder Loss Narrows 42.9% to 408 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1179334791","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179334791?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:42","pubTimestamp":1774960950,"startTime":"0","endTime":"0","summary":"VENUS MEDTECH-B (02500) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 307 million yuan, a decrease of 34.8% compared to the previous year. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02500","BK1100","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623812581","title":"Venus Medtech Hangzhou FY Revenue RMB 306.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623812581","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623812581?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:30","pubTimestamp":1774960247,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nPLX697C11:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02500","BK1574","BK1100","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155513113","title":"ALPHAMAB-B (09966): Phase III Trial of KN026 as Neoadjuvant Therapy for HER2-Positive Breast Cancer Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1155513113","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155513113?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:06","pubTimestamp":1774955203,"startTime":"0","endTime":"0","summary":"ALPHAMAB-B (09966) announced that the Phase III clinical study (Study Code: KN026-004) evaluating KN026 in combination with docetaxel for injection (albumin-bound) (HB1801) as a neoadjuvant treatment...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK4134","BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623835485","title":"Alphamab Oncology - Phase Iii Study of Kn026 With Hb1801 for Her2+ Bc Met Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2623835485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623835485?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:01","pubTimestamp":1774954879,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J0GA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":6,"totalSize":345,"code":"91000000","status":"200"}]}}